Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Clinical Evaluation of Ebola Virus Disease Therapeutics
Guodong Liu
, Gary Wong
, Shuo Su
, Yuhai Bi
, Frank Plummer
, George F. Gao
, Gary Kobinger
, Xiangguo Qiu
Research output
:
Contribution to journal
›
Review article
›
peer-review
21
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical Evaluation of Ebola Virus Disease Therapeutics'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Approved Drugs
20%
Case Fatality Rate
20%
Cause of Disease
20%
Challenges Ahead
20%
Clinical Data
20%
Clinical Evaluation
100%
Clinical Investigation
20%
Clinical Trials
60%
Clinically Approved Drugs
20%
Convalescent Plasma
20%
Diseases Therapeutic
100%
Ebola Outbreak
20%
Ebola Virus Disease
100%
Efficacy Trial
20%
Emergency Situation
20%
Favipiravir
40%
Hemorrhagic Fever
20%
Interferon-α (IFN-α)
20%
Low Viral Load
20%
Nucleoside Analogues
20%
Over 40
20%
Product Basis
20%
Small Interfering RNA (siRNA)
20%
Small Molecule Inhibitors
20%
Survival Benefit
40%
Therapeutic Benefits
20%
Viral Replication
20%
Viral Transcription
20%
West Africa
40%
ZMapp
20%
Medicine and Dentistry
Clinical Trial
100%
Ebolavirus
100%
Favipiravir
33%
Hemorrhagic Fever
16%
Interferon
16%
Mortality Rate
16%
Small Interfering RNA
16%
Viral Transcription
16%
Virus Infection
100%
Virus Replication
16%
ZMapp
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Ebola Virus Disease
100%
Favipiravir
33%
Hemorrhagic Fever
16%
Interferon
16%
Mortality Rate
16%
Small Interfering RNA
16%
ZMapp
16%
Immunology and Microbiology
Blood Plasma
16%
Ebola Virus
100%
Hemorrhagic Fever
16%
interferon
16%
Mortality Rate
16%
Viral Load
16%
Viral Replication
16%
Viral Transcription
16%
ZMapp
16%